Curevo’s lead asset, amezosvatein, is a Phase 3-ready shingles vaccine with potential to increase vaccination rates by delivering improved tolerability versus approved products Seattle, WA – May 26, 2026 – Curevo Vaccine (Curevo), a clinical-stage biotechnology company dedicated to developing varicella zoster virus (VZV) vaccines with improved tolerability, today announced entry into a definitive…Read More
You’ve been a tremendous asset to Coinbase during a very chaotic and complex time. Thank you deeply for everything you’ve done by stepping in to provide guidance and leadership to the team over the last year. Coinbase wouldn’t be where it’s at today without you and I appreciate all you’ve done for this company and our leadership team.
Adam White, Former VP Institutional, Coinbase Read More
